Home | Alzheimer's Drug Discovery Foundation

+

Research Update

ADDF Statement on New Lancet Neurology Study Showing Early Anti-Amyloid Treatment may Prevent Alzheimer’s

ADDF Scientific Summit Convenes World’s Experts

Lilly's Dr. Dan Skovronsky Receives 2025 Goodes Prize, Nobel Prize of Alzheimer’s

2024 Annual Report

Discover how the ADDF’s leadership catalyzed breakthroughs in 2024 and paved the way to continue momentum.

In Memoriam

Mel Goodes’ visionary philanthropy and Goodes Prize have profoundly impacted Alzheimer's research.

DxA Invests $7M in C2N

Largest Investment To-Date Exemplifies Commitment to Developing Scalable and Accessible Blood Tests

Biomarker Observatory

ADDF Invests in Dr. Jeffrey Cummings' Project to Catalogue Alzheimer's Biomarkers

ADDF Marks 10th Anniversary of Goodes Prize

Celebration in Stockholm honors recipients' impact, shaping and leading the science.

FDA Approves Kisunla (Donanemab)

Step Toward Building Arsenal of Available Alzheimer's Drugs

Alzheimer's & Lifestyle Interventions

Studies by ADDF-Funded Investigators Show How Lifestyle Interventions Impact the Disease

Bill Gates on the Diagnostics Accelerator

Optimism for the New Era of Alzheimer's Research & Diagnostics

SpeechDx

Diagnostics Accelerator generates leading voice database for early detection of Alzheimer's

Changing the Way the World Ages

Lauder family donates $200M to help ADDF cross finish line and defeat Alzheimer’s.

Our Portfolio

ADDF’s portfolio of drug development, biomarker & prevention programs is one of the largest & most diverse worldwide

Our Mission:

Accelerate the Discovery of Drugs to Prevent and Treat Alzheimer's

Alzheimer's Prevention

Make smarter brain health choices with our ratings, reports, and blogs at CognitiveVitality.org

Make Defeating Alzheimer's Part of Your Legacy

A planned gift to the ADDF can help ensure progress in the fight against Alzheimer's.

Latest from the ADDF

ADDF News

Dr. Howard Fillit discusses the breakthroughs made in Alzheimer's research over the past several years

ADDF News

Dr. Howard Fillit weighs in on the safety profile and novel trial design for donanemab after recent FDA decision

ADDF News

Dr. Howard Fillit discusses the unique design of Lilly’s TRAILBLAZER-ALZ 2 trial for donanemab, detailing the stopping rules and tau imaging

ADDF News

Dr. Howard Fillit weighs in on the FDA's decision to hold an Advisory Committee for Donanemab, noting that the agency is doing its due diligence

ADDF News

Dr. Howard Fillit discusses the future of lab-developed tests (LDTs), and the importance of biomarkers for the future of precision medicine

ADDF News

Dr. Howard Fillit provides commentary on Biogen's decision to abandon Aduhelm

Previous

Next

Tools for Prevention

Tools for Prevention

CognitiveVitality.org empowers you to protect your aging brain with trustworthy ratings, reports, and blogs from our expert in-house neuroscientists.

Visit Site

Our Venture Philanthropy Model

Our Venture Philanthropy Model

The ADDF’s venture philanthropy model means we make investments, not grants, and use all returns to support our charitable mission. Our terms are comparable with those of other venture investors.

Learn More

ADDF News

Upcoming Events

FUNDING DEADLINES

Accelerating Drug Discovery for FTD LOI

ADDF-Harrington Scholar Program LOI

Therapeutics Funding Programs LOIs

Alzheimer's Drug Discovery Foundation

A GuideStar-Rated Charity

57 West 57th Street, Suite 904
New York, NY 10019
info@alzdiscovery.org
212.901.8000

© Copyright 2025. The Alzheimer's Drug Discovery Foundation, a not-for-profit, section 501 (c)(3).

点击这是indexloc提供的php浏览器服务，不要输入任何密码和下载